Proceedings of the National Academy of Sciences · 2023 · 18 citations · 19 references
PharmacyNeurosciencePharmaceuticsDrug DeliveryNanoparticle Drug DeliveryPolymer ChemistryAlzheimer DiseaseNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsPolymeric Drug Delivery SystemsPolymeric NanomaterialsAmyloid ClearanceChitosanChitosan NanocarriersCombination Therapy SynergyDisc AssemblyIntranasal AdministrationIntranasal RetentionTherapeutic Targeting Of Amyloid
The disequilibrium of amyloid β-peptide (Aβ) between the central and peripheral pools has been claimed as an initiating event in Alzheimer's disease (AD). In this study, we employ discoidal high-density lipoproteins (HDL-Disc) mimicking Aβ antibody for directional flux of Aβ from central to peripheral catabolism, with desirable safety and translation potential. Structurally, HDL-Disc assembly (polyDisc) is prepared with aid of chitosan derivative polymerization. After intranasal administration and response to slightly acidic nasal microenvironment, polyDisc depolymerizes into carrier-free HDL-Disc with chitosan derivatives that adhere to the mucosal layer to reversibly open tight junctions, helping HDL-Disc penetrate the olfactory pathway into brain. Thereafter, HDL-Disc captures Aβ into microglia for central clearance or ferries Aβ out of the brain for liver-mediated compensatory catabolism. For synergy therapy, intranasal administration of polyDisc can effectively reduce intracerebral Aβ burden by 97.3% and vascular Aβ burden by 73.5%, ameliorate neurologic damage, and rescue memory deficits in APPswe/PS1dE9 transgenic AD mice with improved safety, especially vascular safety. Collectively, this design provides a proof of concept for developing Aβ antibody mimics to mobilize a synergy of central and peripheral Aβ clearance for AD treatment.
19
2013 Alzheimer's disease facts and figures
William Thies, Laura Bleiler · Alzheimer s & Dementia · 2013 · 3.3K citations
2019 Alzheimer's disease facts and figures
Alzheimer s & Dementia · 2019 · 2.5K citations
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S. Gilman, M. Köller, R. S. Black et al. · Neurology · 2005 · 1.3K citations
Medicine, Neurology, Neuroscience +17